Ascentage Pharma [AAPG] vs Blueprint Medicines [BPMC] Detailed Stock Comparison
Ascentage Pharma
NASDAQ
Loading...
Blueprint Medicines
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Ascentage Pharma wins in 7 metrics, Blueprint Medicines wins in 8 metrics, with 0 ties. Blueprint Medicines appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ascentage Pharma | Blueprint Medicines | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | -120.99 | N/A |
| Price-to-Book Ratio | 50.60 | 24.43 | Blueprint Medicines |
| Debt-to-Equity Ratio | 608.58 | 208.50 | Blueprint Medicines |
| PEG Ratio | N/A | -137.72 | N/A |
| EV/EBITDA | -46.12 | -53.14 | Blueprint Medicines |
| Profit Margin (TTM) | -41.34% | -27.70% | Blueprint Medicines |
| Operating Margin (TTM) | -361.23% | -27.50% | Blueprint Medicines |
| Return on Equity | -235.32% | -47.71% | Blueprint Medicines |
| Return on Assets (TTM) | -9.25% | -9.75% | Ascentage Pharma |
| Free Cash Flow (TTM) | $-135.65M | $-197.22M | Ascentage Pharma |
| 1-Year Return | 147.93% | 12.60% | Ascentage Pharma |
| Price-to-Sales Ratio (TTM) | 4.06 | 14.89 | Ascentage Pharma |
| Enterprise Value | $1.92B | $8.42B | Blueprint Medicines |
| EV/Revenue Ratio | 14.06 | 14.97 | Ascentage Pharma |
| Gross Profit Margin (TTM) | N/A | 98.12% | N/A |
| Revenue per Share (TTM) | $13 | $9 | Ascentage Pharma |
| Earnings per Share (Diluted) | $-0.74 | $-2.51 | Ascentage Pharma |
| Beta (Stock Volatility) | 0.89 | 0.83 | Blueprint Medicines |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Ascentage Pharma vs Blueprint Medicines Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ascentage Pharma | -2.01% | 15.70% | 1.83% | 77.12% | 129.30% | 146.32% |
| Blueprint Medicines | 0.00% | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ascentage Pharma | 147.93% | 147.93% | 147.93% | 147.93% | 147.93% | 147.93% |
| Blueprint Medicines | 12.60% | 149.54% | 73.38% | 370.76% | 598.65% | 598.65% |
Performance & Financial Health Analysis: Ascentage Pharma vs Blueprint Medicines
| Metric | AAPG | BPMC |
|---|---|---|
| Market Information | ||
| Market Cap | $3.98B | $8.37B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 7,810 | 5,799,940 |
| 90 Day Avg. Volume | 9,017 | 4,343,357 |
| Last Close | $41.95 | $129.46 |
| 52 Week Range | $16.50 - $43.58 | $73.04 - $129.65 |
| % from 52W High | -3.74% | -0.15% |
| All-Time High | $43.58 (Jul 03, 2025) | $129.65 (Jul 16, 2025) |
| % from All-Time High | -3.74% | -0.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.98% | 0.56% |
| Quarterly Earnings Growth | N/A | -0.99% |
| Financial Health | ||
| Profit Margin (TTM) | -0.41% | -0.28% |
| Operating Margin (TTM) | -3.61% | -0.28% |
| Return on Equity (TTM) | -2.35% | -0.48% |
| Debt to Equity (MRQ) | 608.58 | 208.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.85 | $5.30 |
| Cash per Share (MRQ) | $4.06 | $8.92 |
| Operating Cash Flow (TTM) | $-15,513,653 | $-145,552,000 |
| Levered Free Cash Flow (TTM) | $-11,319,065 | $-20,779,750 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Ascentage Pharma vs Blueprint Medicines
| Metric | AAPG | BPMC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | -120.99 |
| Forward P/E | 160.94 | -137.72 |
| PEG Ratio | N/A | -137.72 |
| Price to Sales (TTM) | 4.06 | 14.89 |
| Price to Book (MRQ) | 50.60 | 24.43 |
| Market Capitalization | ||
| Market Capitalization | $3.98B | $8.37B |
| Enterprise Value | $1.92B | $8.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 14.06 | 14.97 |
| Enterprise to EBITDA | -46.12 | -53.14 |
| Risk & Other Metrics | ||
| Beta | 0.89 | 0.83 |
| Book Value per Share (MRQ) | $0.85 | $5.30 |
Financial Statements Comparison: Ascentage Pharma vs Blueprint Medicines
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AAPG | BPMC |
|---|---|---|
| Revenue/Sales | N/A | $149.41M |
| Cost of Goods Sold | N/A | $2.80M |
| Gross Profit | N/A | $146.61M |
| Research & Development | N/A | $91.89M |
| Operating Income (EBIT) | N/A | $-41.09M |
| EBITDA | N/A | $23.55M |
| Pre-Tax Income | N/A | $1.29M |
| Income Tax | N/A | $789,000 |
| Net Income (Profit) | N/A | $496,000 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AAPG | BPMC |
|---|---|---|
| Cash & Equivalents | $1.24B | $122.25M |
| Total Current Assets | $1.47B | $702.07M |
| Total Current Liabilities | $1.17B | $250.58M |
| Long-Term Debt | $889.44M | $409.17M |
| Total Shareholders Equity | $274.16M | $342.13M |
| Retained Earnings | $-5.77B | $-2.41B |
| Property, Plant & Equipment | $0 | $97.66M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AAPG | BPMC |
|---|---|---|
| Operating Cash Flow | N/A | $13.41M |
| Capital Expenditures | N/A | $-1.83M |
| Free Cash Flow | N/A | $-56.31M |
| Debt Repayment | N/A | $-4.11M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AAPG | BPMC |
|---|---|---|
| Shares Short | 15,115 | 3.13M |
| Short Ratio | 1.20 | 0.62 |
| Short % of Float | 0.00% | 0.05% |
| Average Daily Volume (10 Day) | 7,810 | 5,799,940 |
| Average Daily Volume (90 Day) | 9,017 | 4,343,357 |
| Shares Outstanding | 315.22M | 63.71M |
| Float Shares | 240.53M | 60.00M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.00% | 1.09% |
Dividend Analysis & Yield Comparison: Ascentage Pharma vs Blueprint Medicines
| Metric | AAPG | BPMC |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |